acs抗血小板以及.pptVIP

* * 36 * * * * * * During the acute phase, all eligible patients were treated with aspirin and were then randomized to double-blind treatment either with UFH for a minimum of 3 days beginning with a bolus of 70 units/kg and an initial infusion of 15 units/kg/hour to target aPTT of 1.5-2.5 x control (coordinated through an unblinded third party) or enoxaparin given as an intravenous bolus of 30 mg followed by subcutaneous injections of 1 mg/kg every 12 hrs. The primary efficacy endpoint was a composite of all cause mortality, recurrent myocardial infarction based on standard ECG and s